Trial Profile
One-arm, single-center, open-label clinical study of concurrent chemoradiotherapy combined with adjuvant chemotherapy and antiangiogenic therapy for advanced malignant tumors
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 10 Aug 2018 New trial record